Ken Griffin Intercept Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$9.99 - $18.71 $8,451 - $15,828	-846 Reduced 1.02%	81,972 $1.52 Million
Q2 2023 Aug 14, 2023	SELL	$9.17 - $19.29 $707,382 - $1.49 Million	-77,141 Reduced 48.23%	82,818 $915,000
Q1 2023 May 15, 2023	SELL	$12.53 - $21.71 $3.97 Million - $6.89 Million	-317,170 Reduced 66.47%	159,959 $2.15 Million
Q4 2022 Feb 14, 2023	BUY	$11.61 - $16.11 $1.32 Million - $1.84 Million	114,068 Added 31.42%	477,129 $5.9 Million
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $2.86 Million - $4.62 Million	234,277 Added 181.91%	363,061 $5.06 Million
Q2 2022 Aug 15, 2022	BUY	$11.23 - $19.59 $1.25 Million - $2.19 Million	111,553 Added 647.4%	128,784 $1.78 Million
Q1 2022 May 16, 2022	BUY	$13.37 - $17.79 $72,826 - $96,902	5,447 Added 46.22%	17,231 $281,000
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $13,780 - $18,846	965 Added 8.92%	11,784 $191,000
Q3 2021 Nov 15, 2021	SELL	$12.99 - $20.47 $941,736 - $1.48 Million	-72,497 Reduced 87.01%	10,819 $161,000
Q2 2021 Aug 16, 2021	SELL	$15.46 - $24.5 $10 Million - $15.8 Million	-646,812 Reduced 88.59%	83,316 $1.66 Million
Q1 2021 May 17, 2021	BUY	$19.33 - $37.75 $9.87 Million - $19.3 Million	510,589 Added 232.57%	730,128 $16.9 Million
Q4 2020 Feb 16, 2021	BUY	$24.48 - $42.47 $1.1 Million - $1.91 Million	44,949 Added 25.75%	219,539 $5.42 Million
Q3 2020 Nov 16, 2020	SELL	$39.09 - $53.44 $343,796 - $470,004	-8,795 Reduced 4.8%	174,590 $7.24 Million
Q2 2020 Aug 14, 2020	BUY	$46.7 - $92.04 $1.75 Million - $3.46 Million	37,557 Added 25.75%	183,385 $8.79 Million
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $2.03 Million - $4.98 Million	-41,984 Reduced 22.35%	145,828 $9.18 Million
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $15.4 Million - $33.3 Million	-268,481 Reduced 58.84%	187,812 $23.3 Million
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $35.4 Million - $48.6 Million	-603,528 Reduced 56.95%	456,293 $30.3 Million
Q2 2019 Aug 14, 2019	BUY	$77.77 - $120.68 $30 Million - $46.5 Million	385,473 Added 57.16%	1,059,821 $84.3 Million
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $48.6 Million - $63.9 Million	529,313 Added 364.96%	674,348 $0
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $7.57 Million - $11.2 Million	88,192 Added 155.15%	145,035 $14.6 Million
Q3 2018 Nov 13, 2018	SELL	$88.49 - $127.55 $49.2 Million - $71 Million	-556,378 Reduced 90.73%	56,843 $0
Q2 2018 Aug 10, 2018	BUY	$60.0 - $85.67 $34.3 Million - $48.9 Million	570,891 Added 1348.67%	613,221 $0
Q1 2018 May 11, 2018	BUY	$52.72 - $67.25 $744,670 - $949,906	14,125 Added 50.08%	42,330 $2.6 Million
Q3 2017 Nov 09, 2017	BUY	$57.01 - $118.75 $1.61 Million - $3.35 Million	28,205	28,205 $1.64 Million

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account